The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Acquired | Acquired

Total Raised


About HandyLab

HandyLab aims to offer low cost, rapid nucleic acid and protein-based analysis systems for clinical diagnostic markets.

HandyLab Headquarter Location

5230 South State Road Suite 100

Ann Arbor, Michigan, 48108,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

HandyLab Patents

HandyLab has filed 118 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • Molecular biology
  • DNA
patents chart

Application Date

Grant Date


Related Topics




Molecular biology, Biotechnology, DNA, Brass instruments, Ion channels


Application Date


Grant Date



Related Topics

Molecular biology, Biotechnology, DNA, Brass instruments, Ion channels



Latest HandyLab News

Qiagen North America Holdings Inc. v. Handylab, Inc. (Fed. Cir. 2021)

Nov 12, 2021

2021) To embed, copy and paste the code into your website or blog: <iframe frameborder="1" height="620" scrolling="auto" src="//" style="border: 2px solid #ccc; overflow-x:hidden !important; overflow:hidden;" width="100%"></iframe> The inter partes review (IPR) provisions of the Leahy-Smith America Invents Act have been castigated by many for the propensity of the Patent Trial and Appeal Board (PTAB) to find claims challenged in these proceedings to be anticipated or obvious (albeit this outcome has been less frequent for technologies in chemical and life sciences patents). Perhaps one reason for this less predictable negative outcome in these technologies is the countervailing (to some extent) deference the Federal Circuit has been compelled to give Patent and Trademark Office decisions on factual questions (see Dickinson v. Zurko ), and the reliance of anticipation and obviousness rejections on the facts adduced by the parties in IPRs. These considerations came into play recently in the Federal Circuit's non-precedential opinion in Qiagen North America Holdings Inc. v. Handylab, Inc., affirming the PTAB's Final Written Decision (FWD) finding that the claims challenged in the proceeding were non-obvious. The IPRs at issue challenged the claims of Handylab's U.S. Patent No. 7,998,708 and U.S. Patent No. 8,323,900, which are directed to microfluidic systems for amplifying polynucleotides in parallel, i.e., a high throughput screening system for performing reactions like the polymerase chain reaction (PCR) on several samples at the same time. Claim 1 of the '708 patent was reproduced in the opinion as representative of the challenged claims: 1. An apparatus, comprising:     a receiving bay configured to receive the microfluidic cartridge;     each PCR reaction zone comprising a separately controllable heat source thermally coupled thereto, wherein the heat source maintains a substantially uniform temperature throughout the PCR reaction zone and thermal cycles the PCR reaction zone to carry out PCR on a polynucleotide-containing sample in the PCR reaction zone;     a detector configured to detect the presence of an amplification product in the respective PCR reaction zone; and     a processor coupled to the detector and the heat source, configured to control heating of one or more PCR reaction zones by the heat sources. Petitioner Qiagen asserted U.S. Patent No. 6,509,186 in asking the PTAB to find the challenged claims obvious. That reference, according to the opinion, disclosed "a thermal cycler which permits simultaneous treatment of multiple individual samples in independent thermal protocols, so as to implement large numbers of DNA experiments simultaneously in a short time. "  Importantly, the Federal Circuit characterized the '186 patent teachings as disclosing a standalone "multi-chamber thermal cycler chip" having thermally isolated chambers. Qiagen contended that this reference in combination with U.S. Patent Publication No. 2004/0037739 A1 or U.S. Patent Publication No. 2004/0151629 would render the '708 claims obvious, and the '186 patent in combination with the '739 application or U.S. Patent Publication No. 2002/0055,167 would render obvious the challenged claims of the '900 patent. The Board's claim construction was relevant to its determination, wherein the phrase "multi-lane microfluidic cartridge" was construed to mean "a microfluidic cartridge comprising a plurality of sample lanes, each sample lane comprising a separate sample inlet and microfluidic network. "  Under this construction the Board found Petitioner Qiagen had failed to establish obviousness for any of the challenged claims by a preponderance of the evidence on two independent bases. First, the Board held that the '186 patent did not teach a multilane microfluidic cartridge, because the '186 cartridge was configured having all lanes in fluid communication with a single sample inlet comprising a common reservoir. None of the other references asserted by Qiagen remedied this deficiency according to the Board's FWD. The second basis for the Board's non-obviousness determination was that the skilled worker would not have been motivated to combine the prior art references with any reasonable expectation of success, the Petition (in the Board's view) providing only "a single conclusory statement" in this regard. The Board was convinced by Handylab's expert who testified that developing a microfluidic device as claimed was "a very complex endeavor that presented [numerous] challenges. "  Finally, there was an evidentiary dispute wherein the Board refused to consider a Qiagen Exhibit because it was not submitted with the Petition. This appeal followed. The Federal Circuit affirmed, in an opinion by Judge Clevenger, joined by Judges Taranto and Chen. The opinion begins with the Court's determination regarding the Board's conclusion that the skilled worker would not have had a reasonable expectation of success in combining the asserted references to achieve the claimed invention. The panel found substantial evidence supporting the Board's conclusion; indeed, the Court's finding in this regard was sufficient for the panel not to reach any of the other issues in the appeal. First, however, the Court considered whether the Board had properly refused to consider the unsubmitted Exhibit (because this decision impacts the scope of the evidence considered by the Board in reaching its conclusion). Applying an abuse of discretion standard, the panel considered whether Qiagen had satisfied the requirements need to show an abuse of discretion, which according to the opinion only arises if the decision: (1) is clearly unreasonable, arbitrary, or fanciful; (2) is based on an erroneous conclusion of law; (3) rests on clearly erroneous fact findings; or (4) follows from a record that contains no evidence on which the Board could rationally base its decision, citing VidStream LLC v. Twitter, Inc., 981 F.3d 1060, 1064 (Fed. 2020), quoting Shu-Hui Chen v. Bouchard, 347 F.3d 1299, 1307 (Fed. 2003). Under the statutes and regulations governing IPRs, the opinion asserts, a petition must set forth "the evidence that supports the grounds for the challenge to each claim, including [copies of] printed publications that the petitioner relies upon in support of the petition," citing 35 U.S.C. § 312(a)(3), 37 C.F.R. § 42.22(a)(2) and 37 C.F.R. § 42.104(b)(5). The panel opines that Qiagen could have submitted the absent exhibit but did not, nor did the petition "address the general state of the art of the relevant field" (Qiagen contending it was not necessary). Under these circumstances the Federal Circuit held that there was no abuse of discretion in the Board refusing to consider the missing exhibit, particularly in view of the "expedited nature" of IPRs operating under a one-year limit for the Board to render a decision, citing Henny Penny Corp. v. Frymaster LLC, 938 F.3d 1324, 1330 (Fed. 2019), and the PTO's PTAB Consolidated Patent Trial Practice Guide (Nov. 21, 2019). The panel rejected Qiagen's argument that the Board should have considered the missing exhibit on rebuttal because the exhibit was not relevant to the rebuttal arguments Qiagen made (relating to the asserted published applications) but rather asserted the missing exhibit to address the disclosure of the '186 patent reference. Having determined that the scope of evidence properly relied upon by the Board in making its non-obviousness determination to be (primarily) each parties' expert witness testimony, the panel held that there was substantial evidence supporting the Board's holding, including that "Qiagen's Petitions contained only 'a single reference to reasonable expectation of success, in a conclusory statement that "a POSA would have been motivated to combine the multiplexing PCR unit of [the '186 patent] with a conventional integrated machine such as in [the cited published patent applications]'" with a high expectation of success. '"  The testimony of Qiagen's witness did not remedy this lack of evidence on the point, the Board holding that the expert's testimony was "similarly conclusory" (to be fair, perhaps because by denying entry of the missing exhibit into evidence Qiagen's expert did not have a basis to make such statements in his testimony). The Board also relied on positive evidence in the form of Handylab's expert, who provided the basis for the Board's determination that "the development of microfluidic PCR devices was not routine and predictable by March 2006, but rather a very complex endeavor that presented challenges with regard to uniform heating, detection of small volume reactions, contamination, design and configuration of a microfluidic network, and functionally interfacing the reaction instrument with control machinery," that basis being inter alia supported by citation to "numerous contemporary publications in the field. "  Moreover, the opinion asserts, "Qiagen provide[d] no basis for overruling the Board's credibility determinations. "  Coupled with what the panel concluded was "substantial evidence" the Federal Circuit held that the Board's conclusion regarding the complexity of developing microfluidic PCR devices supported the Board's determination that Qiagen had not shown that the skilled worker would have had a reasonable expectation of success for Qiagen to have shown the challenged claims were obvious by a preponderance of the evidence.

  • When was HandyLab founded?

    HandyLab was founded in 2000.

  • Where is HandyLab's headquarters?

    HandyLab's headquarters is located at 5230 South State Road, Ann Arbor.

  • What is HandyLab's latest funding round?

    HandyLab's latest funding round is Acquired.

  • How much did HandyLab raise?

    HandyLab raised a total of $46.45M.

  • Who are the investors of HandyLab?

    Investors of HandyLab include BD, EDF Ventures, Ardesta LLC, Arboretum Ventures, Pfizer Venture Investments and 16 more.

  • Who are HandyLab's competitors?

    Competitors of HandyLab include Novasom, Mirabilis Medical, CyVek, Zonare Medical Systems, Gold Standard Diagnostics and 13 more.

You May Also Like

LifeLineLab S.r.l.

Lifelinelab s.r.l. started its activities in April 2003, thanks to the commitment of three managers coming from the ex Diagnostic Division Manufacturing Plant of Alfa Wassermann S.P.A. First step has been to secure raw materials, and equipment for R&D and Manufacturing of products and services in the field of Human in Vitro Diagnostics. nnnnnFirst diagnostic reagents were manufactured, in this site, over 40 years ago, through the bravery and the enterprising spirit of Prof. Balducci ex Managing Director of Virology Laboratory of "Istituto Superiore di Sanitu00e0". First products were based on tissue colture technology included a line of complement fixation antigens. Since then, the company developed methods and products, covering almost all the fields of Human in Vitro Diagnostics, from Clinical Chemistry to Immunochemistry. The mostly developed sector has been that of Infectious Diseases with particular regard to Viral pathologies. Most products have been developed using biological raw materials derived from in house, in vivo or in vitro, productions. Nowadays the company aims to face and develop markets with consolidate and emerging technologies such as Microarrays using a chemistry patented and designed to covalently bind either Protein or Nucleic acids which aims to allow the development of extremely sophisticated analysis in the emerging applications of proteomics and genomics.

Zoiray Technologies

Zo­ray Technologies Inc. is developing a multiplex immunoassay platform for life science research and clinical diagnostics. Immunoassays that identify the presence of specific protein biomarkers in blood, urine, or saliva constitute a vital tool in modern healthcare. Zo­ray's technology aims to enable many immunoassays to be multiplexed on to one small disposable chip. While multiplexed immunoassays are emerging in life science research, existing techniques require a labeling step that adds variability, inhibit high density arrays, and provide a less quantifiable signal. With simple, inexpensive, label-free protein array detection, Zo­ray expects to make a strong impact in molecular in vitro diagnostics with tests that aim to provide more information than is currently feasible.

Clinical Laboratory Partners

Clinical Laboratory Partners is a provider of clinical diagnostic testing services for healthcare providers, both hospitals and private practices, effectively competing in local markets against a range of national and other local clinical diagnostic laboratories.


G-Nostics is a company in the field of personalised medicine based on the science of pharmacogenetics. The initial product is a diagnostic test, the NicoTest, focused on targeting treatment to aid smoking cessation.


PalindromX Limited (PdX) specialises in developing in vitro diagnostic (IVD) technologies. It is most active in the fields of super-sensitive, multiplexed immunoassay technology, DNA-based vaccination techniques and bone resorption testing services. PdX has generated an intellectual property portfolio in a two areas that is expected to proceed to grant, providing a potentially lucrative future royalty stream. Super sensitive, multiplexed immunoassay; DNA vaccination; bone resorption testing PalindromX Limited (UK) Bone Resorption Services PdX offers a custom in vitro bone resorption testing service to the pharmaceutical, biotechnology and research communities.


Quadraspec is changing the face of diagnostic medicine. Quadraspec's patented SDI label-free detection technology aims to permit the rapid analysis of up to 100 unique tests on up to 1,000 unique patients per hour. Quadraspec's , multiplex-capable diagnostics platform aims to allow high throughput, label-free, highly sensitive bioassays, and diagnostics.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.